John Mendlein, Director at aTYR PHARMA INC (LIFE), bought 245,000 shares at $0.42 ($102K) on 2018-12-21, disclosed to the SEC on 2018-12-26.
Open-market purchase of $102k LIFE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.41 | 50,000 | $21K | 20.0% |
| 2 | $0.42 | 195,000 | $82K | 80.0% |
| Total | $0.42 avg | 245,000 | $102K | 100% |
| Filing → |
| FATE | SELL | 2022-03-11 | $2.2M | — | Filing → |
| LIFE | BUY | 2017-09-05 | $200K | — | Filing → |
| LIFE | BUY | 2017-04-26 | $372 | — | Filing → |